Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

BIOCRYST PHARMACEUTICALS, INC.

(BCRX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/18/2022 11/21/2022 11/22/2022 11/23/2022 11/25/2022 Date
12.43(c) 12.49(c) 12.7(c) 12.39(c) 12.28(c) Last
1 784 769 1 931 807 2 064 581 1 177 091 647 845 Volume
+1.72% +0.48% +1.68% -2.44% -0.89% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 267 M - -
Net income 2022 -212 M - -
Net cash position 2022 54,9 M - -
P/E ratio 2022 -10,9x
Yield 2022 -
Sales 2023 362 M - -
Net income 2023 -166 M - -
Net Debt 2023 130 M - -
P/E ratio 2023 -13,8x
Yield 2023 -
Capitalization 2 289 M 2 289 M -
EV / Sales 2022 8,36x
EV / Sales 2023 6,68x
Nbr of Employees 358
Free-Float 99,0%
More Financials
Company
BioCryst Pharmaceuticals, Inc. (BioCryst) is a commercial-stage biotechnology company that discovers small-molecule medicines. The Company focus on oral treatments for rare diseases in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and... 
Sector
Biotechnology & Medical Research
Calendar
11/29 | 08:25amPresentation
More about the company
Ratings of BioCryst Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about BIOCRYST PHARMACEUTICALS, INC.
11/11BioCryst Presents Real-World Data Showing Rapid and Sustained HAE Attack Rate Reduction..
AQ
11/10BioCryst Presents Real-World Data Showing Rapid and Sustained HAE Attack Rate Reduction..
AQ
11/10Biocryst Presents Real-World Data Showing Rapid and Sustained Hae Attack Rate Reduction..
CI
11/09BioCryst to Present at Upcoming Investor Conferences
AQ
11/07BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635
AQ
11/04BIOCRYST PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Conditi..
AQ
11/04BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
11/02Evercore ISI Upgrades BioCryst Pharmaceuticals to Outperform From In Line With $16 Pric..
MT
11/02RBC Trims BioCryst Pharmaceuticals' Price Target to $13 From $14 on Revised Estimates, ..
MT
11/01BioCryst Pharmaceuticals Q3 Loss Narrows as Revenue Grows
MT
11/01Transcript : BioCryst Pharmaceuticals, Inc., Q3 2022 Earnings Call, Nov 01, 2..
CI
11/01Biocryst : Q3 Earnings Snapshot
AQ
11/01Earnings Flash (BCRX) BIOCRYST PHARMACEUTICALS Reports Q3 Revenue $75.8M, vs. Street Es..
MT
11/01Biocryst Pharmaceuticals Inc : Results of Operations and Financial Condition, Regulation F..
AQ
11/01BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine ..
CI
More news
News in other languages on BIOCRYST PHARMACEUTICALS, INC.
11/10Biocryst présente des données du monde réel montrant une réduction rapide et durable du..
11/01BioCryst Pharmaceuticals réduit sa perte au troisième trimestre et augmente son chiffre..
11/01BioCryst Pharmaceuticals, Inc. annonce ses résultats pour le troisième trimestre et les..
11/01Biocryst Pharmaceuticals, Inc. fournit des prévisions de bénéfices pour l'année 2022
09/14BioCryst Pharmaceuticals nomme un directeur médical en chef
More news
Analyst Recommendations on BIOCRYST PHARMACEUTICALS, INC.
More recommendations
ETFs positioned on BIOCRYST PHARMACEUTICALS, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
ETFMG Treatments Testing and Advancements E...2.95%-1.57%-NC
Virtus LifeSci Biotech Products ETF - USD1.98%-1.29%United_States
ALPS Medical Breakthroughs ETF - USD1.23%0.28%United_States
SPDR S&P Biotech ETF - USD1.02%-0.60%United_States
ETFs S&P Biotech ETF - Distributing - AUD1.02%0.00%-United_States
More ETFs positioned on BIOCRYST PHARMACEUTICALS, INC.
Chart BIOCRYST PHARMACEUTICALS, INC.
Duration : Period :
BioCryst Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOCRYST PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 12,28 $
Average target price 17,60 $
Spread / Average Target 43,3%
EPS Revisions
Managers and Directors
Jon P. Stonehouse Chief Executive Officer & Director
Michael L. Jones Executive Director-Finance
Anthony Doyle Chief Financial Officer
Robert Alexander Ingram Chairman
Helen M. Thackray Chief Research & Development Officer
Sector and Competitors
1st jan.Capi. (M$)
BIOCRYST PHARMACEUTICALS, INC.-11.34%2 289
VERTEX PHARMACEUTICALS42.52%80 339
REGENERON PHARMACEUTICALS, INC.16.44%78 631
BIONTECH SE-39.93%37 632
WUXI APPTEC CO., LTD.-30.90%33 214
GENMAB A/S20.53%28 930